Main Industry
Biotechnology
Main Product/Service
REGiMMUNE’s lead product candidate is RGI-2001, a liposomal small-molecule agent designed to expand regulatory T cells for the prevention of acute graft-versus-host disease (aGvHD). The company also is developing antibody and cell-therapy candidates to ei
Founded Year
2018
Unified Business No.
50779876
Status
Active
Number of Employees
0
Total Paid-in
Capital
240,962,510 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). Their mission is: “Delivering breakthrough immune medicines by harnessing the power of regulatory T cells.”
